Anebulo Ptb Ratio from 2010 to 2024
| ANEB Stock | USD 1.46 0.04 2.67% |
PTB Ratio | First Reported 2010-12-31 | Previous Quarter 18.15162983 | Current Value 19.06 | Quarterly Volatility 485.80436698 |
Check Anebulo Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anebulo Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 261.5 K, Depreciation And Amortization of 245.4 K or Interest Expense of 158.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 19.06. Anebulo financial statements analysis is a perfect complement when working with Anebulo Pharmaceuticals Valuation or Volatility modules.
Anebulo | Ptb Ratio |
Latest Anebulo Pharmaceuticals' Ptb Ratio Growth Pattern
Below is the plot of the Ptb Ratio of Anebulo Pharmaceuticals over the last few years. It is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value. Anebulo Pharmaceuticals' PTB Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anebulo Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Ptb Ratio | 10 Years Trend |
|
Ptb Ratio |
| Timeline |
Anebulo Ptb Ratio Regression Statistics
| Arithmetic Mean | (652.07) | |
| Geometric Mean | 215.15 | |
| Coefficient Of Variation | (74.50) | |
| Mean Deviation | 442.48 | |
| Median | (983.93) | |
| Standard Deviation | 485.80 | |
| Sample Variance | 236,006 | |
| Range | 1K | |
| R-Value | 0.82 | |
| Mean Square Error | 83,516 | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | 89.01 | |
| Total Sum of Squares | 3.3M |
Anebulo Ptb Ratio History
About Anebulo Pharmaceuticals Financial Statements
Anebulo Pharmaceuticals stakeholders use historical fundamental indicators, such as Anebulo Pharmaceuticals' Ptb Ratio, to determine how well the company is positioned to perform in the future. Although Anebulo Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Anebulo Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Anebulo Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Anebulo Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| PTB Ratio | 18.15 | 19.06 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:Check out the analysis of Anebulo Pharmaceuticals Correlation against competitors. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Return On Assets (0.66) | Return On Equity (1.14) |
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.